Celltrion Receives Recommendation for European Marketing Authorization of Autoimmune Disease Treatment CT-P17
[Asia Economy Reporter Lee Junhyung] Celltrion announced on the 11th that it has received a recommendation for marketing authorization from the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) for ‘CT-P17,’ a biosimilar of Humira, an autoimmune disease treatment, for 30 European countries.
CT-P17 is the first biosimilar of Humira developed in a high-concentration formulation and has removed citrate, which can cause pain to patients.
Hot Picks Today
"Could I Also Receive 370 Billion Won?"... No Limit on 'Stock Manipulation Whistleblower Rewards' Starting the 26th
- Samsung Electronics Labor-Management Reach Agreement, General Strike Postponed... "Deficit-Business Unit Allocation Deferred for One Year"
- "From a 70 Million Won Loss to a 350 Million Won Profit with Samsung and SK hynix"... 'Stock Jackpot' Grandfather Gains Attention
- "Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
Celltrion stated, "With this recommendation for approval, we expect the European Commission (EC) to grant final approval in the first half of next year," adding, "Once the EC grants final authorization, CT-P17 will be marketed throughout Europe through Celltrion Healthcare."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
